ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA 98034
Office: (425) 823-0400
Fax: (425) 823-8508
E-mail: info@proteotech.com
A World Leader in Therapeutics and
Diagnostics Targeting Amyloid Diseases
 |
|
ProteoTech's intellectual property estate covering new proprietary technologies currently consists of over 173 patents in its portfolio, including 88 issued patents in the US and Internationally. This extensive portfolio covers technologies relating to:
This extensive landscape of intellectual property covers a wide range of applications including:
April, 2009 ProteoTech presents at the 11th annual C21 BioVentures Conference in Napa, California April, 2009 ProteoTech meets all scientific milestones for the Michael J. Fox foundation LEAPS award to continue development of Synuclere™ for treatment of Parkinson's disease. March 09, 2009 ProteoTech presents at 9th International Conference for Alzheimer's and Parkinson's Disease – Prague, Czech Republic, March 11-15, 2009 February 26, 2009 ProteoTech receives funding from The Michael J. Fox Foundation for Parkinson's Disease research to develop tools for imaging Alpha-Synuclein aggregation in living Parkinson's Brain December, 2008 ProteoTech's Alzheimer's Drug Exebryl-1® was featured in the Dec 2008 Issue of Reader's Digest November 11, 2008 ProteoTech presents at Rodman & Renshaw's 10th Annual Healthcare Conference August 07, 2008 ProteoTech's Exebryl-1® enters human clinical trials for the treatment of Alzheimer's Disease July 29, 2008 Exebryl-1® Phase I human clinical trial for Alzheimer's disease commences July 25, 2008 ProteoTech presents at International Alzheimer's Conference—Chicago, IL. May 28, 2008 ProteoTech receives clearance from FDA to proceed with Phase I human clinical trials for Exebryl-1® May 15, 2008 ProteoTech receives NIH SBIR Phase II continuation award for systemic amyloidosis therapeutic research April 28, 2008 ProteoTech files IND for Exebryl-1® for the treatment of mild-to-moderate Alzheimer's Disease
|
 |
